Dapagliflozin on acute kidney injury and prognosis in patients with diabetes mellitus type 2 and acute coronary syndrome after percutaneous coronary intervention

HAO Huifang; ZHAI Xiufeng; LI Qing; YANG Shicheng; ZHANG Peng

doi:10.6039/j.issn.1001-0408.2025.04.14

您当前的位置：

首页 >

文章列表页 >

Dapagliflozin on acute kidney injury and prognosis in patients with diabetes mellitus type 2 and acute coronary syndrome after percutaneous coronary intervention

更新时间：2025-09-26

- Dapagliflozin on acute kidney injury and prognosis in patients with diabetes mellitus type 2 and acute coronary syndrome after percutaneous coronary intervention
- ZHONGGUO YAOFANG Vol. 36, Issue 4, Pages: 469-474(2025)
- 作者机构：
  
  1.天津市泰达医院肾内科，天津　300451
  2.联勤保障部队天津康复疗养中心，天津　300381
  3.天津市胸科医院心内科，天津　300222
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.04.14
  CLC： R969.4
- Received：01 September 2024，
  
  Revised：2025-02-05，
  
  Accepted：05 February 2025，
  
  Published：28 February 2025
- 稿件说明：
移动端阅览
郝慧芳,窄秀凤,李青,等.达格列净对2型糖尿病合并急性冠脉综合征患者PCI后急性肾损伤及预后的影响[J].中国药房,2025,36(04):469-474.

HAO Huifang,ZHAI Xiufeng,LI Qing,et al.Dapagliflozin on acute kidney injury and prognosis in patients with diabetes mellitus type 2 and acute coronary syndrome after percutaneous coronary intervention[J].ZHONGGUO YAOFANG,2025,36(04):469-474.
郝慧芳,窄秀凤,李青,等.达格列净对2型糖尿病合并急性冠脉综合征患者PCI后急性肾损伤及预后的影响[J].中国药房,2025,36(04):469-474. DOI： 10.6039/j.issn.1001-0408.2025.04.14.

HAO Huifang,ZHAI Xiufeng,LI Qing,et al.Dapagliflozin on acute kidney injury and prognosis in patients with diabetes mellitus type 2 and acute coronary syndrome after percutaneous coronary intervention[J].ZHONGGUO YAOFANG,2025,36(04):469-474. DOI： 10.6039/j.issn.1001-0408.2025.04.14.

摘要

目的

探讨达格列净对2型糖尿病（T2DM）合并急性冠脉综合征（ACS）患者行经皮冠状动脉介入治疗（PCI）后造影剂诱导的急性肾损伤（CIAKI）以及预后的影响。

方法

回顾性收集2021年1月1日至2022年12月31日于天津市胸科医院心内科行PCI治疗的T2DM合并ACS患者资料，根据患者有无应用达格列净，分为达格列净组（96例）和对照组（148例）。记录所有患者PCI前及PCI后48 h、1周的肾功能指标，包括血尿素氮（BUN）、血肌酐（Scr）、估算的肾

小球滤过率（eGFR）、胱抑素C（Cys-C）、肾损伤分子1（KIM-1）、

微球蛋白（

-MG）。所有患者至少随访1年。记录2组患者CIAKI及随访期间主要心血管不良事件（MACE）的发生情况。应用Logistic回归分析使用达格列净对CIAKI发生情况的影响，应用Log-rank检验比较2组之间MACE发生情况的差异，应用Cox回归分析使用达格列净对患者预后的影响。

结果

PCI后48 h及1周，达格列净组患者血Cys-C、KIM-1、

-MG水平均显著低于对照组（

＜0.05）。达格列净组患者CIAKI的发生率显著低于对照组（6.25% vs.14.86%，

＝0.042）；Logistic回归分析结果显示，使用达格列净是CIAKI的独立保护因素（OR＝0.280，95%CI为0.101～0.780，

＝0.015）。随访期间达格列净组患者MACE的发生率显著低于对照组（7.29% vs. 17.57%，

＝0.049）；Cox回归分析结果显示，达格列净可减少PCI后MACE的发生（HR＝0.374，95%CI为0.161～0.866，

＝0.022）。

结论

在水化基础上，使用达格列净并不会增加T2DM合并ACS患者PCI后CIAKI的发生风险。

Abstract

OBJECTIVE

To investigate the impact of dapagliflozin on contrast-induced acute kidney injury （CIAKI） and prognosis in patients with diabetes mellitus type 2 （T2DM） and acute coronary syndrome （ACS） who underwent percutaneous coronary intervention （PCI）.

METHODS

Retrospective selection of data on T2DM patients with ACS who underwent PCI treatment in the Cardiology Department of Tianjin Chest Hospital from January 1st 2021 to December 31st 2022. The patients were divided into dapagliflozin group （96 cases） and control group （148 cases） based on whether they received dapagliflozin or not. Renal function indicators were measured for all enrolled patients before PCI and at 48 h and 1 week after PCI， including blood urea nitrogen （BUN）， serum creatinine （Scr）， estimated glomerular filtration rate （eGFR）， cystatin-C （Cys-C）， kidney injury molecule-1 （KIM-1） and

-microglobulin （

-MG）. All patients were followed up for at least 1 year. The incidence of CIAKI and major adverse cardiac event （MACE） during follow-up were recorded for both groups. Logistic regression was used to analyz

e the impact of dapagliflozin on the occurrence of CIAKI， while the Log-rank test was applied to compare the incidence of MACE between the two groups. Cox regression was employed to analyze the impact of dapagliflozin on prognosis.

RESULTS

At 48 h and 1 week after PCI， serum levels of Cys-C， KIM-1 and

-MG were significantly lower in the dapagliflozin group compared to the control group （

＜0.05）. The incidence of CIAKI was lower in the dapagliflozin group compared to the control group （6.25% vs. 14.86%，

＝0.042）. Logistic regression analysis revealed that dapagliflozin was an independent protective factor against CIAKI （OR＝0.280， 95%CI 0.101-0.780，

＝0.015）. During the follow-up period， the incidence of MACE was lower in the dapagliflozin group compared to the control group （7.29% vs. 17.57%，

＝0.049）. Cox regression analysis indicated that dapagliflozin reduced the occurrence of MACE after PCI （HR＝0.374， 95%CI 0.161-0.866，

＝0.022）.

CONCLUSIONS

With adequate hydration， the use of dapagliflozin does not increase the risk of CIAKI following PCI in T2DM patients with ACS.

关键词

Keywords

references

BRIGUORI C ， QUINTAVALLE C ， MARIANO E ， et al . Kidney injury after minimal radiographic contrast admi-nistration in patients with acute coronary syndromes [J ] . J Am Coll Cardiol ， 2024 ， 83 （ 11 ）： 1059 - 1069 .

张亚梅，马玉凤，杨世诚，等 . 复方丹参滴丸对经皮冠状动脉介入治疗术后对比剂肾病及患者预后的影响 [J ] . 中国药房， 2021 ， 32 （ 15 ）： 1880 - 1884 .

ZHANG Y M ， MA Y F ， YANG S C ， et al . Effects of Compound Danshen dripping pills on contrast-induced nephropathy after percutaneous coronary intervention and patients’ prognosis [J ] . China Pharm ， 2021 ， 32 （ 15 ）： 1880 - 1884 .

PANDEY A K ， BHATT D L ， PANDEY A ， et al . Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction [J ] . Eur Heart J ， 2023 ， 44 （ 37 ）： 3640 - 3651 .

LYU J H ， GUO L Y ， WANG R D ， et al . Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in nondiabetic patients with chronic kidney disease：a review of recent evidence [J ] . Kidney Dis（Basel）， 2023 ， 9 （ 5 ）： 326 - 341 .

巩艳，贺巧艳，杨小娟 . SGLT-2抑制剂引起糖尿病患者急性肾损伤的机制 [J ] . 临床肾脏病杂志， 2021 ， 21 （ 12 ）： 1044 - 1048 .

GONG Y ， HE Q Y ， YANG X J . Mechanisms of acute renal injury caused by SGLT-2 inhibitor in patients with diabetes mellitus [J ] . J Clin Nephrol ， 2021 ， 21 （ 12 ）： 1044 - 1048 .

中华医学会糖尿病学分会，朱大龙 . 中国2型糖尿病防治指南：2020年版 [J ] . 中华糖尿病杂志， 2021 ， 13 （ 4 ）： 315 - 409 .

Chinese Diabetes Society ， ZHU D L . Reaction to guideline for the prevention and treatment of type 2 diabetes mellitus in China：2020 edition [J ] . Chin J Diabetes Mellit ， 2021 ， 13 （ 4 ）： 315 - 409 .

中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管病杂志编辑委员会 . 中国经皮冠状动脉介入治疗指南：2016 [J ] . 中华心血管病杂志， 2016 ， 44 （ 5 ）： 382 - 400 .

The Interventional Cardiology Group of the Cardiovascular Disease Branch of the Chinese Medical Association ， the Thrombosis Prevention and Treatment Professional Committee of the Cardiovascular Physicians Branch of the Chinese Medical Doctor Association ， the Editorial Committee of the Chinese Journal of Cardiovascular Disease . Chinese guidelines for percutaneous coronary intervention：2016 [J ] . Chin J Cardiol ， 2016 ， 44 （ 5 ）： 382 - 400 .

王琳升，张旭东，陆远，等 . 胱抑素C和抗凝血酶Ⅲ对老年高血压患者造影剂急性肾损伤的预测价值 [J ] . 中华老年心脑血管病杂志， 2024 ， 26 （ 8 ）： 862 - 866 .

WANG L S ， ZHANG X D ， LU Y ， et al . Predictive value of cystatin C and antithrombin Ⅲ for contrast-induced acute kidney injury in elderly hypertensive patients [J ] . Chin J Geriatr Heart Brain Vessel Dis ， 2024 ， 26 （ 8 ）： 862 - 866 .

唐巧，李怡，李贵森，等 . 急性肾损伤有关生物标志物的研究进展 [J ] . 实用医院临床杂志， 2022 ， 19 （ 2 ）： 225 - 228 .

TANG Q ， LI Y ， LI G S ， et al . Review of research progress on biomarkers related to acute renal injury [J ] . Pract J Clin Med ， 2022 ， 19 （ 2 ）： 225 - 228 .

马光，程雨佳，滕伟 . 尼可地尔对冠脉造影或支架植入术后造影剂肾病预防作用的Meta分析 [J ] . 中国药房， 2022 ， 33 （ 9 ）： 1119 - 1125 .

MA G ， CHENG Y J ， TENG W . Prevention effects of nicorandil on contrast-induced nephropathy after coronary angiography or stent implantation：a meta-analysis [J ] . China Pharm ， 2022 ， 33 （ 9 ）： 1119 - 1125 .

VEMIREDDY L ， BANSAL S . Contrast-associated acute kidney injury：definitions，epidemiology，pathophysio-logy，and implications [J ] . Interv Cardiol Clin ， 2023 ， 12 （ 4 ）： 489 - 498 .

MURPHY D P ， WOLFSON J ， REULE S ， et al . Kidney outcomes with sodium-glucose cotransporter-2 inhibitor initiation after AKI among veterans with diabetic kidney disease [J ] . Kidney360 ， 2024 ， 5 （ 3 ）： 335 - 343 .

SANTULLI G ， VARZIDEH F ， FORZANO I ， et al . Functional and clinical importance of SGLT2-inhibitors in frailty：from the kidney to the heart [J ] . Hypertension ， 2023 ， 80 （ 9 ）： 1800 - 1809 .

杨世诚，张鹏，丛洪良，等 . 达格列净对老年2型糖尿病患者介入治疗术后造影剂肾病的发生及心血管预后的影响 [J ] . 中华老年心脑血管病杂志， 2024 ， 26 （ 6 ）： 632 - 636 .

YANG S C ， ZHANG P ， CONG H L ， et al . Impact of dapagliflozin on incidence of contrast-induced nephropathy and cardiovascular prognosis in elderly T2DM patients after PCI [J ] . Chin J Geriatr Heart Brain Vessel Dis ， 2024 ， 26 （ 6 ）： 632 - 636 .

卢姗，李立，王声祥，等 . 达格列净致急性肾损伤1例 [J ] . 中南药学， 2022 ， 20 （ 3 ）： 712 - 714 .

LU S ， LI L ， WANG S X ， et al . A case of acute renal injury caused by dapagliflozin [J ] . Cent South Pharm ， 2022 ， 20 （ 3 ）： 712 - 714 .

ZHUO M ， PAIK J M ， WEXLER D J ， et al . SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes [J ] . Am J Kidney Dis ， 2022 ， 79 （ 6 ）： 858 - 867.e1 .

MENNE J ， DUMANN E ， HALLER H ， et al . Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors：a systematic review and meta-analysis [J ] . PLoS Med ， 2019 ， 16 （ 12 ）： e1002983 .

SHI Y J ， DONG S J ， XU Y ， et al . Acute kidney injury events in patients with diabetes using sodium glucose transporter 2 inhibitors：a meta-analysis of cohort studies [J ] . Acta Diabetol ， 2024 ， 61 （ 6 ）： 755 - 764 .

ÇABUK G ， HAZıR K E . Do sodium-glucose cotransporter 2 inhibitors decrease the risk of contrast-associated acute kidney injury in patients with type Ⅱ diabetes mellitus? [J ] . Anatol J Cardiol ， 2024 ， 28 （ 5 ）： 222 - 228 .

FEITOSA M P M ， LIMA E G ， ABIZAID A A C ， et al . The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function：SAFE-PCI pilot study [J ] . Diabetol Metab Syndr ， 2023 ， 15 （ 1 ）： 138 .

毛丽鹏 . 达格列净的应用对急性心肌梗死患者短期预后及急性肾损伤风险的作用 [D ] . 大连：大连医科大学， 2023 .

MAO L P . Effect of dapagliflozin on short-term prognosis and risk of acute renal injury in patients with acute myocardial infarction [D ] . Dalian ： Dalian Medical University ， 2023 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of vericiguat added to GDMT regimen in the treatment of heart failure with reduced ejection fraction

Statistical analysis of adverse drug reactions of Trastuzumab for injection from 2018 to 2023 in Beijing

Associations of MTRR gene polymorphism and methotrexate plasma concentration and adverse drug reaction in children with intracranial tumors

Practice and analysis of clinical pharmacist participating in the treatment of a case of acanthoma caused by navulizumab

曲妥珠单抗联合术前辅助化疗用于Her-2阳性乳腺癌的临床观察

Related Author

XIA Zongling

XUE Hui

WANG Liying

HU Nan

CHEN Xiangyan

ZHAO Xingyuan

ZHANG Wensi

BAI Yu

Related Institution

Dept. of Pharmacy， the Third Affiliated Hospital of Soochow University

Dept. of Pharmacy， the First People’s Hospital of Changzhou

Dept. of Pharmacy， Beijing Cancer Hospital & Beijing Institute for Cancer Research/Key Laboratory of Carcinogenesis and Translational Research， Ministry of Education

Beijing Drug Adverse Event Monitoring Center

Dept. of Pharmacy， Beijing Shijitan Hospital， Capital Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰